Venetoclax clinical trials
Also written Venclexta, ABT-199, GDC-0199 and Venclyxto.
Its developmentBy AbbVie, Hoffmann-La Roche and Oncotherapeutics, step by step67 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.How each study uses venetoclax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the venetoclax studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 11 Apr 2016 · VENCLEXTA · NDA 208573 (FDA, Drugs@FDA)
- European Union
- 4 Dec 2016 · Venclyxto · EMEA/H/C/004106 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
482 studies that test it; most in 2024 (63); 4 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 12 |
| 2015 | 6 |
| 2016 | 10 |
| 2017 | 27 |
| 2018 | 35 |
| 2019 | 36 |
| 2020 | 40 |
| 2021 | 34 |
| 2022 | 59 |
| 2023 | 46 |
| 2024 | 63 |
| 2025 | 51 |
| 2026 | 50 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 83 · Other 403
AbbVie (50) · M.D. Anderson Cancer Center (47) · National Cancer Institute (NCI) (28) · Institute of Hematology & Blood Diseases Hospital, China (24) · The First Affiliated Hospital of Soochow University (23) · Dana-Farber Cancer Institute (12) · City of Hope Medical Center (11) · Hoffmann-La Roche (10)
Often tested with
Tested in the same studies.
Azacitidine (111) · Cytarabine (45) · Obinutuzumab (38) · Decitabine (31) · Ibrutinib (28) · Rituximab (26) · Dexamethasone (21) · Acalabrutinib (15)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 8 phase 3 studies under way
Venetoclax is the comparator. A study of two new drugs counts under both.
- 3Sonrotoclax · BeOne Medicines · next primary completion Sep 2029
- 2Zanubrutinib · BeOne Medicines · next primary completion Feb 2031
- 2Rituximab · BeOne Medicines, Ruijin Hospital · next primary completion Jul 2027
- 1Atezolizumab · Hoffmann-La Roche · next primary completion Jul 2028
- 1Niraparib · Hoffmann-La Roche · next primary completion Jul 2028
- 1Cabozantinib · Hoffmann-La Roche · next primary completion Jul 2028
- 1Galinpepimut-s · Sellas Life Sciences Group
- 1Tacabrutideg · BeOne Medicines · next primary completion May 2028
Reaching primary completion within a year · 87, 8 in phase 3
Studies that test venetoclax, phase 3 first.
- Dec 2026Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical StudyPhase 2/3 · Nanfang Hospital, Southern Medical University
- Dec 2026Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLPhase 3 · The First Affiliated Hospital of Soochow University
- Feb 2027Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)Phase 3 · PedAL BCU, LLC
- Apr 2027Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPhase 3 · Acerta Pharma BV
- Jul 2027Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic SyndromePhase 3 · AbbVie
- Aug 2027An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialPhase 3 · AbbVie
- Sep 2027Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)Phase 3 · German CLL Study Group
- Sep 2027Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaPhase 3 · Chinese PLA General Hospital
- Nov 2026Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin LymphomaPhase 1 · Paolo Caimi, MD
- Nov 2026Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular LymphomaPhase 1/2 · Peter MacCallum Cancer Centre, Australia
Studies
Open first, then newest update. How each study uses venetoclax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 486
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as VenetoclaxHow we know
- Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT07437950Written as VenetoclaxHow we know
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2RecruitingPhase 3University of UlmNCT04628026Written as VenetoclaxHow we know
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT03223610Written as VenetoclaxHow we know
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06317649Written as VenetoclaxHow we know
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT02115295Written as VenetoclaxHow we know
- Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).RecruitingPhase 2M.D. Anderson Cancer CenterNCT06967610Written as VenetoclaxHow we know
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruitingPhase 3National Cancer Institute (NCI)NCT04269902Written as VenetoclaxHow we know
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04840602Written as VenetoclaxHow we know
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruitingPhase 3Kura Oncology, Inc.NCT07007312Written as VenetoclaxHow we know
- A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasRecruitingPhase 1/2The Lymphoma Academic Research OrganisationNCT07018752Written as VenetoclaxHow we know
- Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaNot yet recruitingPhase 1/2Second Affiliated Hospital of Nanchang UniversityNCT07926607Written as VenetoclaxHow we know
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT06649812Written as VenetoclaxHow we know
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as VenetoclaxHow we know
- Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingPhase 2Kerry RogersNCT07734038Written as VenetoclaxHow we know
- Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLNot yet recruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07921550Written as Venetoclax (VEN)How we know
- Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRecruitingPhase 1/2University of WashingtonNCT04797767Written as VenetoclaxHow we know
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingPhase 2City of Hope Medical CenterNCT07582159Written as VenetoclaxHow we know
- Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AMLNot yet recruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07605949Written as VenetoclaxHow we know
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06917911Written as VenetoclaxHow we know
See all 486 studies that test venetoclax →
Given beside what is tested · 186 — venetoclax is usual care or a partner of the new treatment
- Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsRecruitingPhase 2M.D. Anderson Cancer CenterNCT05529069Written as VenetoclaxHow we know
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).RecruitingPhase 3Merck Sharp & Dohme LLCNCT05947851Written as VenetoclaxHow we know
- Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06672146Written as VenetoclaxHow we know
- Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesRecruitingPhase 1/2Nurix Therapeutics, Inc.NCT07520006Written as venetoclaxHow we know
- Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)RecruitingPhase 3PETHEMA FoundationNCT07478991Written as VenetoclaxHow we know
- Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04774393Written as VenetoclaxHow we know
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaRecruitingPhase 1Hoffmann-La RocheNCT05091424Written as VenetoclaxHow we know
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingPhase 3Janssen Research & Development, LLCNCT06852222Written as Venetoclax (VEN)How we know
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML PatientsNot yet recruitingPhase 1Cullinan Therapeutics Inc.NCT07722767Written as VenetoclaxHow we know
- A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDSRecruitingPhase 1Apollo Therapeutics LtdNCT06372717Written as Azacitidine and Venetoclax and APL-4098How we know
- Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia PatientsRecruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07132684Written as VenetoclaxHow we know
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingPhase 1St. Jude Children's Research HospitalNCT06177067Written as VenetoclaxHow we know
- A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)RecruitingPhase 2/3AbbVieNCT07581002Written as VenetoclaxHow we know
- Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 2Jennifer WoyachNCT07557056Written as VenetoclaxHow we know
- Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionRecruitingPhase 1M.D. Anderson Cancer CenterNCT05010772Written as VenetoclaxHow we know
- Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT00501826Written as VenetoclaxHow we know
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingPhase 2/3Taiho Oncology, Inc.NCT04256317Written as VenetoclaxHow we know
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsRecruitingPhase 2M.D. Anderson Cancer CenterNCT07032727Written as VenetoclaxHow we know
- TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid TumorsRecruitingPhase 1Treeline Biosciences, Inc.NCT07713732Written as VenetoclaxHow we know
- Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLLNot yet recruitingPhase 1/2Dana-Farber Cancer InstituteNCT07847957Written as VenetoclaxHow we know
Showing 20 of 186.
As the comparator · 12 — what is tested is compared with venetoclax
- A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsRecruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT07925190Written as VenetoclaxHow we know
- A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsRecruitingPhase 3BeOne MedicinesNCT06846671Written as VenetoclaxHow we know
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingPhase 3BeOne MedicinesNCT06943872Written as VenetoclaxHow we know
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingPhase 3BeOne MedicinesNCT07277231Written as VenetoclaxHow we know
- Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid LeukemiaRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT06532552Written as VAHow we know
- Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingPhase 3Ruijin HospitalNCT06496308Written as VenetoclaxHow we know
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Written as VenetoclaxHow we know
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)Active, not recruitingPhase 3BeOne MedicinesNCT06073821Written as VenetoclaxHow we know
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as VenetoclaxHow we know
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as VenetoclaxHow we know
- Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive InductionWithdrawnPhase 2University of FloridaNCT05766514Written as VenetoclaxHow we know
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedTerminatedPhase 3Gilead SciencesNCT04778397Written as VenetoclaxHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting3
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNov 6, 2026NCT07582159
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaOct 26, 2026NCT05861050
- Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AMLOct 26, 2026NCT07539818
Stopped1
- 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid LeukemiaSuspendedOct 20, 2026NCT05263284
Newly registered2
Codes
What other systems call venetoclax · ClinicalTrials.gg INT006262
- MeSH (NLM) C579720venetoclaxConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) N54AIC43PWVENETOCLAXConfirmed FDA, NLM, Wikidata
- RxNorm 1747556Confirmed FDA, Wikidata
- Wikidata Q23671272venetoclaxConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C103147VenetoclaxOne source FDA
- DrugBank DB11581One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C579720 | venetoclax | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | N54AIC43PW | VENETOCLAX | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1747556 | — | Confirmed FDA, Wikidata |
| Wikidata | Q23671272 | venetoclax | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C103147 | Venetoclax | One source FDA |
| DrugBank | DB11581 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.